Zacks Research Has Bullish Estimate for AbbVie Q1 Earnings

AbbVie Inc. (NYSE:ABBV) – Equities researchers at Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for AbbVie in a report issued on Wednesday, January 14th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $3.01 for the quarter, up from their previous forecast of $2.94. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q2 2026 earnings at $3.71 EPS, Q3 2026 earnings at $3.76 EPS, FY2026 earnings at $14.18 EPS, Q1 2027 earnings at $3.27 EPS, Q2 2027 earnings at $4.03 EPS, Q3 2027 earnings at $4.30 EPS and FY2027 earnings at $15.75 EPS.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.

A number of other equities research analysts also recently commented on ABBV. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research report on Monday, November 3rd. Evercore ISI lifted their price objective on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Piper Sandler reissued an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Bank of America raised their target price on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $247.84.

AbbVie Stock Down 2.4%

ABBV opened at $216.66 on Friday. The stock has a market capitalization of $382.91 billion, a price-to-earnings ratio of 164.13, a PEG ratio of 0.91 and a beta of 0.36. The firm has a 50 day moving average price of $226.89 and a 200-day moving average price of $216.08. AbbVie has a twelve month low of $164.39 and a twelve month high of $244.81.

Institutional Investors Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Balefire LLC increased its position in AbbVie by 73.3% during the second quarter. Balefire LLC now owns 3,679 shares of the company’s stock worth $683,000 after purchasing an additional 1,556 shares during the last quarter. Financiere des Professionnels Fonds d investissement inc. purchased a new position in AbbVie during the second quarter worth about $11,066,000. Finally, Jackson Square Capital LLC raised its stake in AbbVie by 5.2% during the second quarter. Jackson Square Capital LLC now owns 17,609 shares of the company’s stock worth $3,269,000 after purchasing an additional 864 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 496.97%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research raised AbbVie EPS estimates across multiple quarters and lifted FY2026 and FY2027 forecasts (small but consistent upward revisions), indicating analysts see stronger earnings ahead. (Zacks updates)
• Positive Sentiment: Pipeline and clinical progress: AbbVie reported completion of early human/Phase 1 work on ABBV‑CLS‑616 and on GUB014295 (obesity), which derisks parts of the pipeline and supports future growth potential. ABBV‑CLS‑616 phase 1 update GUB014295 trial completion
• Positive Sentiment: Business development and strategy: partnerships (e.g., RemeGen bispecific antibody) and management commentary at JPM underscore management’s push into oncology and obesity as key growth engines. RemeGen partnership Obesity market buildout
• Positive Sentiment: Large call-option buying (≈478k calls in one session) signals aggressive bullish bets from traders; this can amplify upside moves but also raise volatility and gamma risk for holders.
• Neutral Sentiment: Management reiterated a long-term growth story at JPM and features in industry write-ups highlight AbbVie’s pivoted pipeline strategy — useful context for long-term investors but not immediately market-moving. JPM presentation transcript
• Negative Sentiment: Shares have pulled back today (intraday/close weakness vs. broader market). Short-term pressure appears driven by profit-taking and the stock’s rich valuation (reported P/E ~164), which makes investors sensitive to any near-term miss or rotation away from growth names. Zacks: stock dips while market gains

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.